BioStock: Abliva receives FDA Fast Track designation
Swedish biotech Abliva recently received FDA Fast Track designation for KL1333 – the company’s lead drug candidate for mitochondrial disease. KL1333 is currently being evaluated in the potentially registrational phase II study FALCON. BioStock reached out to CEO Ellen K. Donnelly for a comment.Read the full interview with Ellen K. Donnelly at biostock.se: https://www.biostock.se/en/2023/09/abliva-receives-fda-fast-track-designation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/